Prostanoids for the management of glaucoma

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 801-808

  Arranz Marquez, Esther ^a   Teus, Miguel A ^a,b,c  

^a VISSUM Corporacion Oftalmologica   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Bimatoprost; Glaucoma; Hypotensive drugs; IOP; Latanoprost; PGF2 analogues; Prostaglandin analogues; Prostanoids; Travoprost; Unoprostone

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 6; FIBRONECTIN; GELATINASE A; GELATINASE B; HYALURONIC ACID; INTERSTITIAL COLLAGENASE; LAMININ; LATANOPROST; PROSTAGLANDIN RECEPTOR; STROMELYSIN; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

ANGINA PECTORIS; AQUEOUS HUMOR FLOW; ARTICLE; ASTHMA; BRONCHOSPASM; CILIARY MUSCLE; CONJUNCTIVAL HYPEREMIA; CORNEA EROSION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EVENING DOSAGE; EXTRACELLULAR MATRIX; GLAUCOMA; HERPES SIMPLEX KERATITIS; HUMAN; INTRAOCULAR PRESSURE; IRIS DISEASE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; MUSCLE RELAXATION; PATIENT COMPLIANCE; PEER REVIEW; RECEPTOR UPREGULATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; EYE COLOR; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; IRIS; OCULAR HYPERTENSION; PIGMENTATION; PROSTAGLANDINS;

EID: 57049094554     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802465474     Document Type: Article

References (62)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
2. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85
3. de Voogd S, Ikram MK, Wolfs RCW, et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112:1487-93
4. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002;11:531-9
5. Quigley HA. New paradigms in the mechanisms and management of glaucoma. Eye 2005;19:1241-8
6. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol 2001;85:1277-82
7. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
8. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
9. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
10. Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 2004;13:221-6
11. Kurzrok C, Lieb C. Biochemical studies on human semen: action of semen on the human uterus. Proc Soc Exp Biol Med 1930;28:268-72
12. Miyake K, Shirasawa E, Hikita M. Hypotheses on the role of prostaglandins in the pathogenesis of epinephrine maculopathy and aphakic cystoid macular edema. In: Bito LZ, Stjernschantz J, editors, The ocular effects of prostaglandins and other eicosanoids, Alan R Liss, Inc., New York; 1989. p. 265-76
13. Resul B, Stjernschantz J, Selen G, Bito LZ. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 1997;41(Suppl 2):S47-52
14. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003;305:772-85
15. Konstas AGP, Boboridis K, Tzetzi D, et al. Twenty four hour control with latanoprost-timolol fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005;123:898-902
16. Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res 1998;17:291-312
17. Cheng-Bennett A, Poyer J, Weinkam RJ, Woodward DF. Lack of prostaglandin F2 alpha metabolism by human ocular tissues. Invest Ophthalmol Vis Sci 1990;31:1389-93
18. Sjoquist B, Johansson A. Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories. Arzneimittelforschung 1999;49:240-9
19. Alm A, Widengård I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-6
20. Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001;131:798-9
21. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008;115:790-5
22. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
23. Bahler CK, Howell KG, Hann CR, et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 2008;145:114-9
24. Orzalesi N, Rosseti L, Invernizzi T, et al. Effect of timolol, latanoprost and dorzolamide on circadian IOP in glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566-73
25. Crownston JG, Lindsay JD, Morris CA, et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 2005;46:4571-7
26. Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707-16
27. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;38:2772-80
28. Weinreb RN, Lindsey JD, Marchenko G, et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci 2004;45:4368-77
29. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2a treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794-801
30. Watson PG, Latanoprost study group. Latanoprost two years' experience of its use in the United Kingdom. Ophthalmology 1998;105:82-7
31. Parrish RK, Palmberg P, Sheu WP; for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
32. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002;47(Suppl 11):S65-76
33. Rossetti L, Gandolfi S, Traverso C, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma 2006;15:238-43
34. Camras CB, Alm A, Watson P, Stjernschantz J, the Latanoprost Study Group. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996;103:1916-24
35. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37
36. Arranz-Marquez E, Teus MA. Relation between axial length of the eye and hypotensive effect of latanoprost in primary open angle glaucoma. Br J Ophthalmol 2004;88:635-7
37. Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin f2α receptor gene and response to latanoprost. Ophthalmology 2007;114:1039-45
38. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104
39. Aung T, Wong HT, Yip CC, et al. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma. Ophthalmology 2000;107:1178-83
40. Serle JB, Podos SM, Kitazawa Y, Wang RF. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 1998;42:95-100
41. Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure lowering efficacy of bimatoprost 0,03% and travoprost 0,004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:1336-7
42. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/ Latanoprost Study Group. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 2004;49(Suppl 1):S19-25
43. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-14
44. Arranz Marquez E, Teus Guezala MA, Canseco Gonzalez F. Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD). Arch Soc Esp Oftalmol 2002;77:553-8
45. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004;122:957-65
46. Alm A, Stjernschantz J; the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102:1743-52
47. Lass JH, Eriksson GL, Osterling L, Simpson CV; Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 2001;108:264-71
48. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratins. Am J Ophthalmol 1999;127:602-4
49. Lindén C, Nuija E, Alm A. Effects on intraocular pressure restoration and blood aqueous barrier after long-term treatment with latanoprost in POAG and ocular hypertension. Br J Ophthalmol 1997; 81:370-2
50. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol 2000;11:94-100
51. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time course of latanoprost induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(Suppl):S129-38
52. Teus MA, Arranz-Marquez E, Lucea-Suescun P. Incidence of iris color change in latanoprost treated eyes. Br J Ophthalmol 2002;86:1085-8
53. Lindsey JD, Jones HL, Hewitt EG, et al. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol 2001;119:853-60
54. Arranz-Marquez E, Teus MA. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. Ophthalmology 2007;114:1255-8
55. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res 1999;69:431-6
56. Pfeiffer N, Grierson I, Goldsmith H, et al. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study. Arch Ophthalmol 2001;119:191-6
57. Camras CB, Neely DG, Weiss EL. Latanoprost-induced iris color darkening: a case report with long-term follow-up. J Glaucoma 2000;9:95-8
58. Pfeiffer N, Grierson I, Goldsmith H, et al. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study). Arch Ophthalmol 2003;121:23-31
59. Arranz-Marquez E, Teus MA, Saornil MA, Mendez C. Analysis of irises with a latanoprost-induced change in iris color. Am J Ophthalmol 2004;138:626-31
60. Cracknell KPB, Grierson I, Hogg P. Morphometric effects of long-term exposure to latanoprost. Ophthalmology 2007;114:938-48
61. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47(Suppl 1):S185-202
62. Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced periocular skin changes in Caucasians. Ophthalmology 2006;113:1961-7